RecruitingPhase 3NCT06246149
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Studying Uveal melanoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Paul Nathan, Ph.DMount Vernon Cancer Centre, Northwood, UK
- Intervention
- Tebentafusp(drug)
- Enrollment
- 290 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2032
Study locations (14)
- Cliniques Universitaires Saint-Luc, Brussels, Belgium
- Centre Antoine Lacassagne, Nice, France
- Institut Curie - Hôpital de Paris, Paris, France
- Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
- Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center, Hamburg, Germany
- Universitaetsklinikum Heidelberg - Frauenklinik / Hautklinik, Heidelberg, Germany
- Leiden University Medical Centre, Leiden, Netherlands
- Erasmus MC, Rotterdam, Netherlands
- Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia), L'Hospitalet de Llobregat, Spain
- Hospital Clinico Universitario De Valladolid, Valladolid, Spain
- Sahlgrenska Universitetssjukhuset, Gothenburg, Sweden
- The Clatterbridge cancer Center NHS foundation Trust - Clatterbridge Cancer Center - Liverpool, Liverpool, United Kingdom
- East and North Hertfordshire NHS Trust - Mount Vernon Hospital, Northwood, United Kingdom
Collaborators
Northwell Health · Immunocore Ltd
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06246149 on ClinicalTrials.govOther trials for Uveal melanoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07364474Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverMassachusetts General Hospital
- RECRUITINGPHASE3NCT07015190Neoadjuvant Darovasertib in Primary Uveal MelanomaIDEAYA Biosciences
- RECRUITINGPHASE2NCT07276386Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1, PHASE2NCT06961357Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1NCT07203391Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisSt Vincent's Hospital, Sydney
- RECRUITINGPHASE1NCT07076550A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic MelanomaAlpha-9 Oncology USA Inc.
- RECRUITINGNCT07421739Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) SubjectsAura Biosciences
- RECRUITINGPHASE1, PHASE2NCT06626516Tebentafusp-tebn With LDT in Metastatic UMThomas Jefferson University